Online Inquiry
ARID1A (Q456*/Q456*) Cell Line
SPL-00403
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| ARID1A (Q456*/Q456*) |
| Target Information | |
|---|---|
| Target Name | ARID1A |
| Gene Abbr. | ARID1A |
| Gene ID | 8289 |
| Full Name | AT-rich interaction domain 1A |
| Alias | B120, BAF250, BAF250a, BM029, C1orf4 |
| Species | Human |
| Genomic Locus | 1p35.3 |
| Introduction | This gene encodes a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. It possesses at least two conserved domains that could be important for its function. First, it has a DNA-binding domain that can specifically bind an AT-rich DNA sequence known to be recognized by a SNF/SWI complex at the beta-globin locus. Second, the C-terminus of the protein can stimulate glucocorticoid receptor-dependent transcriptional activation. It is thought that the protein encoded by this gene confers specificity to the SNF/SWI complex and may recruit the complex to its targets through either protein-DNA or protein-protein interactions. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]. |
| Product Details | |
|---|---|
| Cell Line Model | MCF10A |
| Genotype | ARID1A (Q456*/Q456*) |
| Description | ARID1A (Q456*/Q456*) |
| Parental ATCC ID | CRL-10317 |
| STR Profile | Amelogenin: X; CSF1PO: 10,12; D13S317: 8,9; D16S539: 11,12; D5S818: 10,13; D7S820: 10,11; THO1: 8,9.3; TPOX: 9,11; vWA: 15,17; ATCC |
| Disease | Epithelial |
| Tissue | Breast |
| Gender | Female |
| Key Endogenous Mutations | none listed |
| CVT Selection Condition | G418 resistant - 0.1 mg/mL; Hygromycin resistant - 0.01 mg/mL |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Culture Medium | DMEM/F-12 including 2.5 mM L-glutamine and 15 mM HEPES, supplemented with 5% horse serum, 10 µg/mL insulin, 20 ng/mL hEGF, 0.5 µg/mL hydrocortisone, 0.1 µg/mL cholera toxin. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.